## Paclitaxel

### Summary of evidence and Expert Committee recommendations

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for paclitaxel on the complementary list of the EML for use in treatment protocols for nasopharyngeal cancer was specifically endorsed. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for nasopharyngeal cancer is attached.

### ATC codes: L01CD01

**Indication**
- Malignant neoplasms of nasopharynx

**INN**
- Paclitaxel

**Medicine type**
- Chemical agent

**List type**
- Complementary

**Formulations**
- Parenteral > General injections > IV: 6 mg per mL

**EML status history**
- First added in 2015 (TRS 994)

**Sex**
- All

**Age**
- Adolescents and adults

**Therapeutic alternatives**
- The recommendation is for this specific medicine

**Patent information**
- Patents have expired in most jurisdictions
- Read more about patents.

**Tags**
- Cancer

**Wikipedia**
- Paclitaxel

**DrugBank**
- Paclitaxel

---

**Essential medicine status**

**ATC codes:** L01CD01

**Indication**
- Malignant neoplasms of nasopharynx

**INN**
- Paclitaxel

**Medicine type**
- Chemical agent

**List type**
- Complementary

**Formulations**
- Parenteral > General injections > IV: 6 mg per mL

**EML status history**
- First added in 2015 (TRS 994)

**Sex**
- All

**Age**
- Adolescents and adults

**Therapeutic alternatives**
- The recommendation is for this specific medicine

**Patent information**
- Patents have expired in most jurisdictions
- Read more about patents.

**Tags**
- Cancer

**Wikipedia**
- Paclitaxel

**DrugBank**
- Paclitaxel